Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes.Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Related Products:
Alirocumab; Denosumab; Eculizumab; Evolocumab; Omalizumab; Ustekinumab; Vedolizumab; Trastuzumab; Omalizumab; Nivolumab; Denosumab; Cetuximab; Bevacizumab; Aflibercept